B+
Bull case
25%
Probability
Target price
$0.36
Analysis reference price unavailable
Analysis 2026-10-26 · RankAlpha Sentiment Codex
ACH
Accendra HealthCNYSE / Health Care Equipment & Services
Last Price
Quote time unavailable
Current thesis
The June debt reduction, planned cost savings, and sleep-care and commercial initiatives could support a recovery if second-half results validate guidance. The deterministic prior is positive, but the operating evidence does not yet warrant a bullish upgrade.
Posture
Mixed
Lead driver
Value
What changed
Next scheduled catalyst: earnings 2026-11-05 · AMC.
What can break
Full-year guidance requires a substantial second-half adjusted-EBITDA and free-cash-flow improvement from first-half results. [#SEC-8K-2026-08-10]
Momentum
78
Value
54
Sentiment
48
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $0.22 · Bull $0.36 · Bear $0.10Analysis 2026-10-26; returns require an exact persisted reference.
Earnings
2026-11-05 · AMC
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-29 • Vendor: Data Vendor v1
Scores
As of 2026-10-29 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-26 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-29
Investment thesis
As of 2026-10-29
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-29. Definitions
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $1.25
Why
Momentum78 · Δ7d -
Value54 · Δ7d +0.1
Sentiment48 · Δ7d -
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Confirming evidence
- • Next scheduled catalyst: earnings 2026-11-05 · AMC.
- • Value remains the lead driver in the composite, 7D delta +0.1.
Contradictions & invalidation
- • Full-year guidance requires a substantial second-half adjusted-EBITDA and free-cash-flow improvement from first-half results. [#SEC-8K-2026-08-10]
- • Low coverage, an unverified analyst-target sample size, and a very low share price make percentage price outcomes unusually uncertain.
- • Second-quarter revenue fell to $613.2 million from $681.9 million a year earlier, adjusted EBITDA fell to $60.1 million from $96.6 million, and free cash flow was negative $25.1 million.
Catalyst clock
2026-11-05 · AMC
November 5 third-quarter results test the recovery
Lead driver: Value · See fundamentals
Momentum
78
8% active weight
Current posture
7d trendSoftening
Δ7d
-
Δ21d
-
Value
54
47% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.1
Sentiment
48
45% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade C. Momentum 78.2 / Value 54.2 / Sentiment 48.0
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-26. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$0.22
Analysis reference price unavailable
Analysis 2026-10-26 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$0.10
Analysis reference price unavailable
Analysis 2026-10-26 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-29
Fundamentals (TTM)
As of 2026-10-29
Market Cap
$17.92M
Beta
1.38
Shares Out
76.9M
P/E (TTM) · Derived
-0.0
P/S (TTM)
0.02
P/FCF (TTM) · Derived
-0.05
Rev YoY
-10.1%
EPS YoY
-89.7%
Gross Margin
+39.9%
Op Margin
+1.4%
Net Debt
$1.88B
Current Ratio
0.41
As of 2026-10-29 • Updated nightlySource: Internal modelMethods & Data